Drug firm Sun Pharma today said it has received the US regulator's approval for the generic version of Acular, used to treat pain and swelling after eye surgeries.
The US Food and Drug Administrator (USFDA) has granted approval for the Abbreviated New Drug Application (ANDA) for the generic version of Acular, which is also known as Ketotrolac Tromethamine Opthalmic Solution, Sun Pharma said in a filing to the Bombay Stock Exchange.
US-based drug firm Allergan Inc has patent rights over Ketotrolac Tromethamine Opthalmic Solution and the company is selling the drug under the brand Acular.
The drug is indicated for the temporary relief of ocular itching due to seasonal allergic conductivities, it said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app